GAMMA Investing LLC Boosts Holdings in Humana Inc. (NYSE:HUM)

GAMMA Investing LLC increased its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 40,881.1% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 781,099 shares of the insurance provider's stock after purchasing an additional 779,193 shares during the period. GAMMA Investing LLC owned 0.65% of Humana worth $2,066,790,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Transcend Capital Advisors LLC increased its stake in Humana by 399.7% in the 4th quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider's stock worth $924,000 after acquiring an additional 2,914 shares during the last quarter. Retirement Systems of Alabama increased its stake in Humana by 735.9% in the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider's stock worth $55,563,000 after acquiring an additional 192,801 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Humana by 7.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider's stock worth $244,811,000 after acquiring an additional 65,735 shares during the last quarter. denkapparat Operations GmbH bought a new position in Humana in the 4th quarter worth about $323,000. Finally, South Dakota Investment Council increased its stake in Humana by 39.9% in the 4th quarter. South Dakota Investment Council now owns 153,317 shares of the insurance provider's stock worth $38,898,000 after acquiring an additional 43,719 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Stock Up 1.3%

Humana stock traded up $3.01 on Tuesday, hitting $234.40. 468,445 shares of the stock traded hands, compared to its average volume of 1,718,849. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market cap of $28.29 billion, a P/E ratio of 23.56, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49. The business's fifty day simple moving average is $256.32 and its 200 day simple moving average is $266.21. Humana Inc. has a 1 year low of $212.45 and a 1 year high of $406.46.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating the consensus estimate of $10.07 by $1.51. The business had revenue of $32.11 billion during the quarter, compared to analyst estimates of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. The company's revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter last year, the firm posted $7.23 earnings per share. As a group, sell-side analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.51%. The ex-dividend date is Friday, June 27th. Humana's dividend payout ratio is presently 25.04%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on HUM shares. Robert W. Baird upped their price objective on Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a report on Tuesday, April 15th. Raymond James upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a report on Thursday, May 1st. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. JPMorgan Chase & Co. cut their price objective on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Finally, Wall Street Zen upgraded Humana from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Sixteen investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $284.48.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.